TrialHuman vaccines & immunotherapeutics2026
NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants.
Xuan Ying Poh et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.